Evaluation of Antibacterial Activity of cLFchimera and its Synergistic Potential with Vancomycin against Methicillin-Resistant Staphylococcus aureus

Sahar Roshanak; Fakhri Shahidi; Atefeh Soradeghi Toopkanloo; Zana Pirkhezranian; Mohammad Hadi Sekhavati

Evaluation of Antibacterial Activity of cLFchimera and its Synergistic Potential with Vancomycin against Methicillin-Resistant Staphylococcus aureus

2022

Sahar Roshanak | Fakhri Shahidi | Atefeh Soradeghi Toopkanloo | Zana Pirkhezranian | Mohammad Hadi Sekhavati

Frequent and unlimited use of antibiotics caused the development of antibiotic resistance by microorganisms. Therefore, there is an argent need to discover novel antibacterial agents or a combination of agents as a safe treatment strategy for various infections. In the present study the synergistic effects of cLFchimera, an antimicrobial peptides, and Vancomycin antibiotic were evaluated using checkerboard method against Methicillin Resistant Staphylococcus aureus (MRSA) bacteria strain. cLFchimera had antimicrobial activity against MRSA and Methicillin Sensitive Staphylococcus aureus (MSSA) (MIC: 256 and 512 µg/mL, respectively). A synergistic effect was observed in the combination of cLFchimera with Vancomycin (FIC: 0.375). The results showed that at FIC concentrations, release cytoplasmic materials from bacterial cells and the number of surviving cells were significantly (P≤0.05) higher and lower, respectively, than when peptides or antibiotic were used alone. SEM electron microscopic analysis at FIC concentration showed severe membrane damage of bacterial cells. In conclusion, the use of cLFchimera and Vancomycin at FIC concentration reduces the consumption of both substances.

اظهر المزيد [+]